PURPOSE: To evaluate tumor volume reduction in the follow-up of meningiomas after fractionated stereotactic radiotherapy (FSRT) or linac radiosurgery (RS) by using magnetic resonance imaging (MRI). PATIENTS AND METHODS: In 59 patients with skull base meningiomas, gross tumor volume (GTV) was outlined on contrast-enhanced MRI before and median 50 months (range 11-92 months) after stereotactic radiotherapy. MRI was performed as an axial three-dimensional gradient-echo T1-weighted sequence at 1.6 mm slice thickness without gap (3D-MRI). Results were compared to the reports of diagnostic findings. RESULTS: Mean tumor size of all 59 meningiomas was 13.9 ml (0.8-62.9 ml) before treatment. There was shrinkage of the treated meningiomas in all but one patient. Within a median volumetric follow-up of 50 months (11-95 months), an absolute mean volume reduction of 4 ml (0-18 ml) was seen. The mean relative size reduction compared to the volume before radiotherapy was 27% (0-73%). Shrinkage measured by 3D-MRI was greater at longer time intervals after radiotherapy. The mean size reduction was 17%, 23%, and 30% (at < 24 months, 24-48 months, and 48-72 months). CONCLUSION: By using 3D-MRI in almost all patients undergoing radiotherapy of a meningioma, tumor shrinkage is detected. The data presented here demonstrate that volumetric assessment from 3D-MRI provides additional information to routinely used radiologic response measurements. After FSRT or RS, a mean size reduction of 25-45% can be expected within 4 years.
PURPOSE: To evaluate tumor volume reduction in the follow-up of meningiomas after fractionated stereotactic radiotherapy (FSRT) or linac radiosurgery (RS) by using magnetic resonance imaging (MRI). PATIENTS AND METHODS: In 59 patients with skull base meningiomas, gross tumor volume (GTV) was outlined on contrast-enhanced MRI before and median 50 months (range 11-92 months) after stereotactic radiotherapy. MRI was performed as an axial three-dimensional gradient-echo T1-weighted sequence at 1.6 mm slice thickness without gap (3D-MRI). Results were compared to the reports of diagnostic findings. RESULTS: Mean tumor size of all 59 meningiomas was 13.9 ml (0.8-62.9 ml) before treatment. There was shrinkage of the treated meningiomas in all but one patient. Within a median volumetric follow-up of 50 months (11-95 months), an absolute mean volume reduction of 4 ml (0-18 ml) was seen. The mean relative size reduction compared to the volume before radiotherapy was 27% (0-73%). Shrinkage measured by 3D-MRI was greater at longer time intervals after radiotherapy. The mean size reduction was 17%, 23%, and 30% (at < 24 months, 24-48 months, and 48-72 months). CONCLUSION: By using 3D-MRI in almost all patients undergoing radiotherapy of a meningioma, tumor shrinkage is detected. The data presented here demonstrate that volumetric assessment from 3D-MRI provides additional information to routinely used radiologic response measurements. After FSRT or RS, a mean size reduction of 25-45% can be expected within 4 years.
Authors: A T Villavicencio; P M Black; D C Shrieve; M P Fallon; E Alexander; J S Loeffler Journal: Acta Neurochir (Wien) Date: 2001-11 Impact factor: 2.216
Authors: Iris Zachenhofer; Stefan Wolfsberger; Martin Aichholzer; Alexander Bertalanffy; Karl Roessler; Klaus Kitz; Engelbert Knosp Journal: Neurosurgery Date: 2006-01 Impact factor: 4.654
Authors: Bruce E Pollock; Scott L Stafford; Andrew Utter; Caterina Giannini; Shawn A Schreiner Journal: Int J Radiat Oncol Biol Phys Date: 2003-03-15 Impact factor: 7.038
Authors: Martin Henzel; Klaus Hamm; Helmut Sitter; Markus W Gross; Gunnar Surber; Gabriele Kleinert; Rita Engenhart-Cabillic Journal: Strahlenther Onkol Date: 2009-09-12 Impact factor: 3.621
Authors: R A Bundschuh; N Andratschke; J Dinges; M N Duma; S T Astner; M Brügel; S I Ziegler; M Molls; M Schwaiger; M Essler Journal: Strahlenther Onkol Date: 2012-03-24 Impact factor: 3.621
Authors: A Zabel-du Bois; S Milker-Zabel; M Henzel; W Popp; J Debus; H Sack; R Engenhart-Cabillic Journal: Strahlenther Onkol Date: 2012-08-01 Impact factor: 3.621
Authors: M J R Runge; M Maarouf; S Hunsche; M Kocher; M I Ruge; F El Majdoub; H Treuer; R-P Mueller; J Voges; V Sturm Journal: Strahlenther Onkol Date: 2012-02-22 Impact factor: 3.621
Authors: Ralph A Bundschuh; Christina M Wendl; Gregor Weirich; Mathias Eiber; Michael Souvatzoglou; Uwe Treiber; Hubert Kübler; Tobias Maurer; Jürgen E Gschwend; Hans Geinitz; Anca L Grosu; Sibylle I Ziegler; Bernd Joachim Krause Journal: Eur J Nucl Med Mol Imaging Date: 2013-02-07 Impact factor: 9.236